Auswahl der wissenschaftlichen Literatur zum Thema „Amyotrophic lateral sclerosis – patients“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Amyotrophic lateral sclerosis – patients" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Amyotrophic lateral sclerosis – patients"
Nakayama, Yui, Satoru Morimoto, Misao Yoneda, Shigeki Kuzuhara und Yasumasa Kokubo. „Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex“. Journal of Neurodegenerative Diseases 2013 (27.03.2013): 1–4. http://dx.doi.org/10.1155/2013/679089.
Der volle Inhalt der QuelleFreischmidt, Axel, Kathrin Müller, Lisa Zondler, Patrick Weydt, Alexander E. Volk, Anže Lošdorfer Božič, Michael Walter et al. „Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers“. Brain 137, Nr. 11 (05.09.2014): 2938–50. http://dx.doi.org/10.1093/brain/awu249.
Der volle Inhalt der QuelleVoitenkov, Vladislav B., und E. V. Ekusheva. „Pain in amyotrophic lateral sclerosis“. Journal of Clinical Practice 10, Nr. 2 (17.08.2019): 66–73. http://dx.doi.org/10.17816/clinpract10266-73.
Der volle Inhalt der QuelleLi, Lian, Jie Liu und Hua She. „Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis“. CNS & Neurological Disorders - Drug Targets 18, Nr. 5 (23.09.2019): 366–71. http://dx.doi.org/10.2174/1871527318666190409103831.
Der volle Inhalt der QuelleIngre, Caroline, Lin Chen, Yiqiang Zhan, Jet Termorshuizen, Li Yin und Fang Fang. „Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis“. Neurology 94, Nr. 17 (27.03.2020): e1835-e1844. http://dx.doi.org/10.1212/wnl.0000000000009322.
Der volle Inhalt der QuelleGeevasinga, Nimeshan, James Howells, Parvathi Menon, Mehdi van den Bos, Kazumoto Shibuya, José Manuel Matamala, Susanna B. Park, Karen Byth, Matthew C. Kiernan und Steve Vucic. „Amyotrophic lateral sclerosis diagnostic index“. Neurology 92, Nr. 6 (11.01.2019): e536-e547. http://dx.doi.org/10.1212/wnl.0000000000006876.
Der volle Inhalt der QuelleSathasivam, Sivakumar. „Managing patients with amyotrophic lateral sclerosis“. European Journal of Internal Medicine 20, Nr. 4 (Juli 2009): 355–58. http://dx.doi.org/10.1016/j.ejim.2008.09.002.
Der volle Inhalt der QuelleVerhey, F. R. J., F. W. Vreeling und J. Jolles. „Dementia and Amyotrophic Lateral Sclerosis“. Acta Neuropsychiatrica 4, Nr. 1 (März 1992): 17–20. http://dx.doi.org/10.1017/s0924270800034967.
Der volle Inhalt der QuelleCividini, Camilla, Silvia Basaia, Edoardo G. Spinelli, Elisa Canu, Veronica Castelnovo, Nilo Riva, Giordano Cecchetti et al. „Amyotrophic Lateral Sclerosis–Frontotemporal Dementia“. Neurology 98, Nr. 4 (01.12.2021): e402-e415. http://dx.doi.org/10.1212/wnl.0000000000013123.
Der volle Inhalt der QuelleOliveira Filho, Ademar Francisco de, Gêssyca Adryene de Menezes Silva und Débora Milenna Xavier Almeida. „Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review“. Einstein (São Paulo) 14, Nr. 3 (September 2016): 431–34. http://dx.doi.org/10.1590/s1679-45082016rb3594.
Der volle Inhalt der QuelleDissertationen zum Thema "Amyotrophic lateral sclerosis – patients"
Bradley, Lloyd John. „Mitochondrial abnormalities in remote tissues of patients with amyotrophic lateral sclerosis“. Thesis, University College London (University of London), 2006. http://discovery.ucl.ac.uk/1445375/.
Der volle Inhalt der QuelleKasi, Patrick K. „Characterization of motor unit discharge rate in patients with amyotrophic lateral sclerosis“. Worcester, Mass. : Worcester Polytechnic Institute, 2009. http://www.wpi.edu/Pubs/ETD/Available/etd-050409-062647/.
Der volle Inhalt der QuelleLee, Rena J. „Study of trace and minor elements in ALS (amyotrophic lateral sclerosis) patients“. Thesis, Massachusetts Institute of Technology, 1994. http://hdl.handle.net/1721.1/36492.
Der volle Inhalt der QuelleOudenot, Hélèna. „Indirect Estimation of Persistent Inward Currents in Patients with Amyotrophic Lateral Sclerosis“. Thesis, KTH, Tillämpad fysik, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-192844.
Der volle Inhalt der QuelleTeyssou, Elisa. „Analyses génétiques et fonctionnelles de nouveaux gènes incriminés dans la Sclérose Latérale Amyotrophique (SLA) Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients Genetic analysis of CHCHD10 in French familial amyotrophic lateral sclerosis patients“. Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066738.
Der volle Inhalt der QuelleThe fatal Amyotrophic Lateral Sclerosis (ALS) motor neuron disease is characterized by the degeneration of upper and lower motor neurons. Most ALS cases are sporadic (SALS) whereas ~10% are familial (FALS). A growing number of genes has been identified in ALS and represent 70% of FALS and 10% of SALS. The aims of this project were to analyze the contribution of 6 rare genes in a large population of French ALS patients and to study the pathogenic impact of some identified variants.The first part of this work was dedicated to the genetic analysis of MATR3, CHCHD10, SS18L1, SQSTM1, UBQLN2 and PFN1 genes. No causing variants were identified for MATR3 and CHCHD10 while 2 new variants, probably pathogenic, were identified for SS18L1, as well as 4 mutations for SQSTM1, 5 for UBQLN2 and 2 already reported mutations for PFN1. These analyses also highlighted a genetic overlap between ALS and other diseases: the Paget disease of bone for SQSTM1 and spastic paraplegia for UBQLN2. The second part of this work was to study the pathogenicity of some of the mutations identified in SQSTM1, UBQLN2 and PFN1 genes using analyses of (i) inclusions in ALS patient post-mortem tissue, (ii) protein expression and degradation pathways in patient lymphoblasts and/or (iii) cellular consequences after in vitro and in vivo overexpression. Our results showed prominent aggregation of mutant SQSTM1 (involved in autophagosomes formation), impaired lysosomal degradation and disrupted protein binding to HSP70 for mutant UBQLN2 and deregulated alternative autophagy and mitophagy pathways for mutant PFN1. Our results (i) precised the contribution of several genes in French ALS patients, (i) documented the genetic overlap between ALS and other diseases and (iii) highlighted the role of protein degradation pathways, especially autophagy, in the pathogenesis of ALS
Lemoignan, Josée. „Decision-making for assisted ventilation in amyotrophic lateral sclerosis“. Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=101862.
Der volle Inhalt der QuelleAchille, Marie A. „Attitudes toward assisted suicide among patients with amyotrophic lateral sclerosis and their caregivers“. Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape10/PQDD_0023/NQ51830.pdf.
Der volle Inhalt der QuelleCamara, Mafalda Dias de Medeiros Vale da. „Coherence and phase locking disruption in electromyograms of patients with amyotrophic lateral sclerosis“. Master's thesis, Faculdade de Ciências e Tecnologia, 2013. http://hdl.handle.net/10362/10950.
Der volle Inhalt der QuelleIn motor neuron disease, the aim of therapy is to prevent or slow neuronal degeneration and early diagnosis is thus essential. Hypothesising that beta-band (15-30 Hz) is a measure of pathways integrity as shown in literature, coherence and PLF could be used as an electrophysiological indicator of upper and lower neuron integrity in patients with ALS. Before further analysis, synthetic EMG signals were computed to verify the used algorithm. Coherence and PLF analyses were performed for instants of steady contraction from contra and ipsilateral acquisitions. Ipsilateral acquisitions were performed for one member of each group and results present significant differences between both groups. Contrarily, contralateral acquisitions were performed on 6 members of each group and results present no significant differences. PLF analysis was computed for ipsilateral acquisitions and, similarly to coherence, results show significant differences between both groups. PLF was also analysed for contralateral acquisitions, and results show no significant differences within groups, as expected since no coherence was found for the same acquisitions. So, while control subjects present no neuronal or muscular problems and therefore higher synchrony and coherence for beta-band frequencies, patients with ALS do not present synchronism or coherence in any frequency, specially for beta-band. All results allowed to conclude that contralateral coherence is not a good measure of corticospinal pathways integrity. However, ipsilateral acquisitions show promising results and it is possible to affirm that ipsilateral measurements may reflect neuronal degeneration. For future work is suggested a deeper analysis of PLF, that appear to have potential as a quantitative test of upper and lower neuron integrity related to ALS.
BENEDETTI, S. DE. „SPORADIC AMYOTROPHIC LATERAL SCLEROSIS IN PATIENTS WITH COMMON GEOGRAPHICAL ORIGIN: A MULTIDISCIPLINARY STUDY“. Doctoral thesis, Università degli Studi di Milano, 2017. http://hdl.handle.net/2434/486489.
Der volle Inhalt der QuelleOsei-Lah, Abena Dansoa. „Intracortical excitability is altered in patients with amyotrophic lateral sclerosis : a transcranial magnetic stimulation study“. Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415039.
Der volle Inhalt der QuelleBücher zum Thema "Amyotrophic lateral sclerosis – patients"
Hiroshi, Mitsumoto, Hrsg. Amyotrophic lateral sclerosis: A guide for patients and families. 3. Aufl. New York, NY: Demos Health, 2009.
Den vollen Inhalt der Quelle findenHiroshi, Mitsumoto, und Munsat Theodore L. 1930-, Hrsg. Amyotrophic lateral sclerosis: A guide for patients and families. 2. Aufl. New York: Demos, 2001.
Den vollen Inhalt der Quelle findenParker, James N., und Philip M. Parker. The official patient's sourcebook on amyotrophic lateral sclerosis. Herausgegeben von Icon Group International Inc. San Diego, Calif: Icon Health Publications, 2003.
Den vollen Inhalt der Quelle findenT, Caroscio James, Hrsg. Amyotrophic lateral sclerosis: A guide to patient care. New York: Thieme, 1986.
Den vollen Inhalt der Quelle findenDavid, Oliver. Motor neurone disease. 2. Aufl. London: Royal College of General Practitioners, 1994.
Den vollen Inhalt der Quelle findenYi, Kyu-yŏn. Nun ŭro hŭimang ŭl ssŭda: Lugerik kwa matsŏ ssaun kijŏk ŭi kŏin Pak Sŭng-il ŭi hŭimang ilgi. 8. Aufl. Sŏul-si: Ungjin Chisik Hausŭ, 2009.
Den vollen Inhalt der Quelle findenKoka, Halil. Bana ALS teşhisi koydular: Bir ALS hastasının umut dolu savaşı. İstanbul: Cinius, 2010.
Den vollen Inhalt der Quelle findenBalmer, Sonja. Atemlos: Aufzeichnungen zwischen Beatmungsmaschine, Schläuchen und Computer. 2. Aufl. Zürich: Limmat Verlag, 2006.
Den vollen Inhalt der Quelle findenMassachusetts. Bureau of Environmental Health. Environmental Epidemiology Program. The Amyotrophic Lateral Sclerosis (ALS) Disease Registry: Frequently asked questions for patients and families. Boston, Mass.]: Massachusetts Department of Public Health, Bureau of Environmental Health, Environmental Epidemiology Program, 2009.
Den vollen Inhalt der Quelle findenStinton, William M. I choose to live: A journey through life with ALS. Gurnee, IL: Banbury Pub., 2003.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "Amyotrophic lateral sclerosis – patients"
Cesa-Bianchi, M., und F. Ravaccia. „Psychological Preparation of the Physician for ALS Patients“. In Amyotrophic Lateral Sclerosis, 311–12. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_45.
Der volle Inhalt der QuelleFerro, F. M., G. Riefolo, D. A. Nesci und S. Mazza. „Psychodynamic Aspects in Patients with Amyotrophic Lateral Sclerosis (ALS)“. In Amyotrophic Lateral Sclerosis, 313–16. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_46.
Der volle Inhalt der QuelleNorris, F. H., D. Holden, K. Kandal und E. Stanley. „Home Nursing Care by Families for Severely Paralyzed ALS Patients“. In Amyotrophic Lateral Sclerosis, 231–38. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_35.
Der volle Inhalt der QuelleSinaki, M. „Physical Therapy and Rehabilitation Techniques for Patients with Amyotrophic Lateral Sclerosis“. In Amyotrophic Lateral Sclerosis, 239–52. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_36.
Der volle Inhalt der QuelleDelodovici, M. L., E. Terazzi, C. Pasetti und P. Pinelli. „Analysis of Extrinsic Factors Affecting Pallestesic Threshold (VT) Of Amyotrophic Lateral Sclerosis Patients“. In Amyotrophic Lateral Sclerosis, 125–28. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_20.
Der volle Inhalt der QuellePinelli, P., L. Mazzini, G. Mora, F. Pisano und A. Villani. „A Follow-Up Electromyographic Investigation of ALS Patients Treated with High Dosage Gangliosides“. In Amyotrophic Lateral Sclerosis, 285–90. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_41.
Der volle Inhalt der QuelleMaher, I., A. Pouplard-Barthelaix und J. Emile. „Cytotoxicity of Serum from Amyotrophic Lateral Sclerosis Patients on Spinal Cord Cells in Culture“. In Amyotrophic Lateral Sclerosis, 75–77. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_12.
Der volle Inhalt der QuelleDelwaide, P. J., und J. Schoenen. „Spinal Cord Electrophysiological Activities After Small Doses of TRH in Control Subjects and ALS Patients“. In Amyotrophic Lateral Sclerosis, 129–33. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-5302-7_21.
Der volle Inhalt der QuelleLane, Giulia, und Paholo Barboglio Romo. „Amyotrophic Lateral Sclerosis and Motor Neuron Disorders“. In Urological Care for Patients with Progressive Neurological Conditions, 127–34. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23277-1_14.
Der volle Inhalt der QuelleShravani, T., Ramya Sai, M. Vani Shree, J. Amudha und C. Jyotsna. „Assistive Communication Application for Amyotrophic Lateral Sclerosis Patients“. In Computational Vision and Bio-Inspired Computing, 1397–408. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37218-7_147.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Amyotrophic lateral sclerosis – patients"
Aquino, Letícia, Juliana Victor dos Santos, Jaqueline Donola Scandoleira, Jéssica Elen Gonçalves Nascimento und Letícia Moraes de Aquino. „Telerehabilitation in Amyotrophic Lateral Sclerosis“. In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.528.
Der volle Inhalt der QuellePascual Martinez, Natalia, María Melgar Herrero, Cristina Gómez Rebollo und Elisa Martínez Repiso. „How Our Amyotrophic Lateral Sclerosis Patients Die“. In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3419.
Der volle Inhalt der QuelleVieira, Marina Duarte Gama, Anna Letícia Siqueira de Medeiros, Narayna Suellen Santos da Silva und Edlene Lima Ribeiro. „Dysphagia in patients with amyotrophic lateral sclerosis“. In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.398.
Der volle Inhalt der QuellePyarali, F., R. Lewis, F. Diaz und A. Elsayegh. „Differentiating Spirometric Features Between Patients with Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis“. In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2207.
Der volle Inhalt der QuelleTsai, Jang-Zern, und Tsai-Shih Chen. „Eye-writing communication for patients with amyotrophic lateral sclerosis“. In Proceeding of the eleventh international ACM SIGACCESS conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1639642.1639694.
Der volle Inhalt der QuelleEspiritu, Noelle Marie D., Senrong Ainsley C. Chen, Tiffany Ann C. Blasa, Francisco Emmanuel T. Munsayac, Rebecca P. Arenos, Renann G. Baldovino, Nilo T. Bugtai und Homer S. Co. „BCI-controlled Smart Wheelchair for Amyotrophic Lateral Sclerosis Patients“. In 2019 7th International Conference on Robot Intelligence Technology and Applications (RiTA). IEEE, 2019. http://dx.doi.org/10.1109/ritapp.2019.8932748.
Der volle Inhalt der QuelleKurmi, Om Prakash, Manasi Gyanchandani, Nilay Khare und Arvind Pillania. „Classification of Amyotrophic Lateral Sclerosis Patients using speech signals“. In 2023 Third International Conference on Secure Cyber Computing and Communication (ICSCCC). IEEE, 2023. http://dx.doi.org/10.1109/icsccc58608.2023.10176797.
Der volle Inhalt der QuelleHuang, Yixiao, Xiaoli Wu und Rosa H. M. Chan. „Stratification and Survival Prediction for Amyotrophic Lateral Sclerosis Patients“. In 2022 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI). IEEE, 2022. http://dx.doi.org/10.1109/bhi56158.2022.9926946.
Der volle Inhalt der QuelleKasi, Patrick K., Lisa S. Krivickas, Melvin Meister, Effie Chew, Maurizio Schmid, Gary Kamen, Edward A. Clancy und Paolo Bonato. „Motor unit firing characteristics in patients with amyotrophic lateral sclerosis“. In 2009 IEEE 35th Annual Northeast Bioengineering Conference. IEEE, 2009. http://dx.doi.org/10.1109/nebc.2009.4967680.
Der volle Inhalt der QuelleDalla Vecchia, Laura, Anna Lucini, Domenico Volza, Riccardo Sideri, Kalliopi Marinou und Gabriele Mora. „Cardiac neural regulation involvement in patients with amyotrophic lateral sclerosis“. In 2014 8th Conference of the European Study Group on Cardiovascular Oscillations (ESGCO). IEEE, 2014. http://dx.doi.org/10.1109/esgco.2014.6847539.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Amyotrophic lateral sclerosis – patients"
Santos, Ana Lúcia Yaeko da Silva, Deyse Mayara Rodrigues Caron, Livia Shirahige und Abrahão Fontes Baptista. Alterations in Corticomotor Excitability in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Mai 2023. http://dx.doi.org/10.37766/inplasy2023.5.0078.
Der volle Inhalt der QuelleAnklesaria, Pervin. Preclinical Development of Therapeutics for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2009. http://dx.doi.org/10.21236/ada541412.
Der volle Inhalt der QuelleConnor, James R. Apo-Ferritin as a Therapeutic Treatment for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada567828.
Der volle Inhalt der QuellePrzedborski, Serge. Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada567841.
Der volle Inhalt der QuelleConnor, James R. Apo-Ferritin as a Therapeutic Treatment for Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, Dezember 2013. http://dx.doi.org/10.21236/ada598852.
Der volle Inhalt der QuelleGrill, Raymond J. Targeted Riluzole Delivery by Antioxidant Nanovectors for Treating Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2014. http://dx.doi.org/10.21236/ada613439.
Der volle Inhalt der QuelleGrill, Raymond J. Targeted Riluzole Delivery by Antioxidant Nanovectors for Treating Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2013. http://dx.doi.org/10.21236/ada598451.
Der volle Inhalt der QuelleLoGrasso, Philip, und Serge Przedborski. c-jun-N-Terminal Kinase (JNK) for the Treatment of Amyotrophic Lateral Sclerosis. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2013. http://dx.doi.org/10.21236/ada596507.
Der volle Inhalt der QuelleWackerman, Brooke L., B. L. Cox, K. L. Grayson, Shari L. Shanklin und Wilson W. McGriff. Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers. Fort Belvoir, VA: Defense Technical Information Center, April 2005. http://dx.doi.org/10.21236/ada437518.
Der volle Inhalt der QuelleZhu, Qiaochu, Jin Zhou, Hai Huang, Jie Han, Biwei Cao, Dandan Xu, Yan Zhao und Gang Chen. Risk factors associated with amyotrophic lateral sclerosis: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0118.
Der volle Inhalt der Quelle